Basic Information
PROVERA TABLET 5 mg
TABLET
Regulatory Information
SIN10513P
December 3, 1998
Prescription Only
Therapeutic
ORAL
August 10, 2023
May 30, 2025
XG03DA02
Company Information
Active Ingredients
Strength: 5 mg
Detailed Information
Contraindications
**4.3 Contraindications** MPA is contraindicated in patients with the following conditions: - Known or suspected pregnancy - Undiagnosed vaginal bleeding - Severe liver dysfunction - Known hypersensitivity to MPA or any component of the drug - Thrombophlebitis - Thromboembolic disorders - Cerebral apoplexy or patients with a past history of these conditions - Missed abortion - Known or suspected malignancy of the breast
Indication Information
**4.1 Therapeutic Indication** **Gynecology** Medroxyprogesterone acetate (MPA) tablets are indicated for: - Treatment of secondary amenorrhea. - Treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer.